02 / 2025 FORTBILDUNG: THEMENHEFTTEIL KINDERÄRZTE. SCHWEIZ 35 LITERATUR 1 Faraone, S. V., & Buitelaar, J. (2010). Comparing the efficacy of stimulants for ADHD in children and adolescents using meta- analysis. European Child & Adolescent Psychiatry, 19(4), 353-364. https://doi.org/10.1007/s00787-009-0054-3 2 https://www.swissinfo.ch/ger/wissenschaft/massiv-mehr-ritalin/ 2643634 3 Zhang et. al. (2022). Risk of cardiovascular diseases associated with medications used in attention-deficit/hyperactivity disorder: A systematic review and meta-analysis. JAMA Network Open, 5(11), e2243597. https://doi.org/10.1001/jamanetworkopen. 2022.43597 4 Stevenson, R. D., & Wolraich, M. L. (1989). Stimulant medication therapy in the treatment of children with attention deficit hyperactivity disorder. Pediatric Clinics of North America, 36(5), 11831197. 5 Hennissen, L. et al. (2017). Cardiovascular effects of stimulant and non-stimulant medication for children and adolescents with ADHD: A systematic review and meta-analysis of trials of methylphenidate, amphetamines and atomoxetine. CNS Drugs, 31(3), 199-215. https://doi.org/10.1007/s40263-017-0410-7 6 Cooper et al. (2011). ADHD drugs and serious cardiovascular events in children and young adults. New England Journal of Medicine, 365(20), 1896-1904. https://doi.org/10.1056/NEJMoa1110212 7 Graham et al. (2011). European guidelines on managing adverse effects of medication for ADHD. European Child & Adolescent Psychiatry, 20(1), 17-37. https://doi.org/10.1007/s00787-0100140-6 8 Vetter et al. (2008). Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder: A scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation, 117(18), 2407-2423. https://doi.org/10.1161/CIRCULATIONAHA.107.189473 9 Mahle et al. (2009). Electrocardiographic screening in children with attention-deficit hyperactivity disorder. The American Journal of Cardiology, 104(9), 1296-1299. https://doi.org/10.1016/ j.amjcard.2009.06.052 10 Tang, J., Wei, Y., Yin, C., Lu, B., Yan, Y., Chen, M., Cao, S., Li, L., & Zhang, Y. (2022). The Risk of Attention-Deficit/Hyperactivity Disorder Among Children With Congenital Heart Disease: A Systematic Review and Meta-analysis. JAMA Network Open, 5(9), e2232521. https://doi.org/10.1001/jamanetworkopen.2022.32521 11 Trairatvorakul, P., Visitsunthorn, N., Satdhabudha, A., & Vijarnsorn, C. (2018). Stimulant medication treatment in children with congenital heart disease and attention-deficit/hyperactivity disorder: Cardiovascular outcomes. Pediatric Cardiology, 39(1), 157– 165. https://doi.org/10.1007/s00246-017-1745-z Bild: Sophia Bild: Elina
RkJQdWJsaXNoZXIy MjYwNzMx